Quest Diagnostics Inc (DGX) announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
The Focus Diagnostics Simplexa Influenza A H1N1 (2009) test employs real-time reverse transcription polymerase chain reaction to qualitatively detect the 2009 H1N1 flu virus in a patient's nasal or nasopharyngeal specimens. The test targets a region of the hemagglutinin gene of the 2009 H1N1 influenza virus specifically to detect the presence of 2009 H1N1 influenza RNA, thereby differentiating it from seasonal human influenza A viruses.
For comments and feedback: editorial@rttnews.com